FDA Approves Bictegravir-Lenacapavir Combination Pill for Suppressed HIV
Source Summary
Gilead Sciences announced FDA approval of Bixlenvo, a once-daily single tablet combining bictegravir and lenacapavir, for adults with virologically suppressed HIV-1 infection. The tablet contains 75 mg of bictegravir and an unspecified dose of lenacapavir.
Why it matters
This approval provides a new once-daily treatment option for people with suppressed HIV, potentially simplifying medication regimens.
